Financial Analysis: Aspira Women’s Health (NASDAQ: AWH) and Heska (NASDAQ: HSKA)
$0.05 2,552.60
Heska has higher revenue and earnings than Aspira Women’s Health. Aspira Women’s Health is trading at a lower price-to-earnings ratio than Heska, indicating that it is presently the extra cost effective of both supplies.
Summary
Heska defeats Aspira Women’s Health on 11 of the 14 factors contrasted between the two supplies.
Concerning Aspira Women’s Health
Aspira Women’s Health Inc., along with its subsidiaries, uncovers, develops, and markets bio-analytical and also analysis services that assist physicians to identify, treat, and also improve gynecologic wellness end results for women in the United States. The firm offers markets OVA1, ova1plus, and overa risk of hatred examinations for ovarian cancer cells. It likewise offers ASPiRA GenetiX, a hereditary test for particular women’s health and wellness diseases. In addition, the business has as well as operates ASPiRA LABS, a lab that specializes in applying biomarker-based modern technologies to attend to vital demands in the administration of gynecologic cancers cells and condition. Better, it is establishing analysis algorithms, along with a high-risk screening formula for individuals who are genetically inclined to ovarian cancer cells. The firm serves doctors, physician office research laboratories, and hospital laboratories. The firm was previously called Vermillion, Inc. and also transformed its name to Aspira Women’s Health Inc. in June 2020. Aspira Women’s Health Inc. was started in 1993 as well as is headquartered in Austin, Texas.
Concerning Heska
Heska Corporation makes, offers, and markets vet diagnostic as well as specialized products for feline and canine healthcare markets in the United States, Canada, Europe, and also globally. The business’s Other Vaccines and Pharmaceuticals segment supplies a line of bovine injections; pharmaceutical and biological products for various other animal wellness business; as well as various complete services comprising research study, licensing, packaging, manufacturing, and labeling, as well as gives validation support as well as circulation services. The business was previously understood as Paravax, Inc. and altered its name to Heska Corporation in 1995.